{"id":"W1967792499","doi":"10.1056/nejmoa1406470","title":"Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2071,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenvatinib; Medicine; Refractory (planetary science); Thyroid cancer; Fibroblast growth factor receptor; Receptor; Internal medicine; Thyroid; Placebo; Vascular endothelial growth factor; Endocrinology; Oncology; Cancer research; Fibroblast growth factor; VEGF receptors; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06912991086914029,"score_gpt":0.3433677123675156,"score_spread":0.2742378014983753,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}